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INT ROD UCT ION
Persisting viral infections remain a major global medical 
problem, as over 500 million people are infected long term 
with hepatitis B or C or HIV (Alter, 2006). Independent from 
the outcome, viral infections typically induce large numbers 
of pathogen-specific T cells (Murali-Krishna et al., 1998; 
Badovinac et al., 2007; Williams and Bevan, 2007; Virgin et 
al., 2009). Yet, it remains vaguely understood why effector 
CD8 T cells support the elimination of the majority of viral 
infections but frequently fail to eliminate hepatitis C virus 
or HIV. Data from human acute and chronic infections and 
studies performed in acute or chronic lymphocytic chorio-
meningitis virus (LCMV)–infected mice show tight correla-
tions between the phenotype T cells acquire during a viral 
infection and success or failure in clearing it (Wherry et al., 
2003; Klenerman and Hill, 2005; Day et al., 2006; Virgin et 
al., 2009; Schietinger and Greenberg, 2014; Speiser et al., 
2014). In resolved infections, T cells typically acquire a so-
called polyfunctional phenotype, which refers to the ability 
of T cells to cosecrete high levels of IFN-γ and TNF and, 
upon transition to memory, also IL-2 (Harari et al., 2008). 
In contrast, T cells in chronic infections are impaired in their 
ability to produce TNF, IFN-γ, or IL-2 (Wherry et al., 2007). 
Moreover, they typically retain expression of inhibitory re-
ceptors such as PD-1, LAG-3, 2B4, CD160, and Tim3, which 
are only temporarily expressed in acute infections (Wherry 
et al., 2007; Blackburn et al., 2009). These phenotypic partic-
ularities were first described in persisting LCMV infections. 
Subsequently, they were also found in HIV and hepatitis C 
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virus infections (Day et al., 2006; Radziewicz et al., 2007; 
Wherry et al., 2007; Bengsch et al., 2010; Legat et al., 2013; 
Schietinger and Greenberg, 2014), but they are absent or 
occur much less prominently in EBV and latent CMV infec-
tions (Klenerman and Hill, 2005; Hertoghs et al., 2010). The 
presence of this chronic phenotype is typically viewed as a 
sign of a deteriorating T cell response, linked to a substantial 
loss of antiviral activity.
The concept that persisting infections exhaust a func-
tional immune response is widely accepted (Moskophidis 
et al., 1993; Zajac et al., 1998; Wherry, 2011; Pauken and 
Wherry, 2015). Nonetheless, it contrasts with clinical and ex-
perimental observations, which indicate that critical levels of 
effector function are retained in persisting infections (Speiser 
et al., 2014; Zehn et al., 2016). This is underlined by obser-
vations that depleting CD8 T cells from established simian 
immunodeficiency virus infections in rhesus macaques leads 
to strong increases in virus titers (Jin et al., 1999; Schmitz 
et al., 1999) and by data showing that T cells express high 
granzyme B levels and can select epitope escape variants even 
in the chronic phase of LCMV clone-13 infections (Wherry 
et al., 2007; Johnson et al., 2015). The most prominent evi-
dence of retained T cell function stems from the many studies 
demonstrating that T cell function and virus clearance can 
be significantly augmented by blocking inhibitory recep-
tors (predominately PD-1; Barber et al., 2006; Blackburn et 
al., 2008; Nakamoto et al., 2009; Jin et al., 2010; Bengsch et 
al., 2014). These observations do not preclude that T cells in 
chronic infections are fundamentally different from T cells in 
acute infections, but they are difficult to align with the idea 
that T cells transition to a nonfunctional state. Instead, these 
examples question which functional properties are lost, main-
tained, or even gained by T cells in chronic infections. For 
instance, the expression of inhibitory receptors such as PD-1, 
which is typically seen as a sign of deterioration, might in 
fact reflect a gain of an additional feature, which is that the 
effector function of such T cells can be tuned (or attenuated) 
by PD-L1–expressing antigen-positive target cells (Frebel et 
al., 2012). Related to this, it was recently shown that PD-1 
signaling serves a protective function and prevents a rapid de-
terioration of the T cell response (Odorizzi et al., 2015).
Along these lines, we previously reported that when 
T cells from chronic infections are adoptively transferred 
into naive host mice and reexpanded by an acute infection, 
they continue to display the cytokine and PD-1 expression 
profile of T cells in chronic infections (Utzschneider et al., 
2013). This leads to the conclusion that T cells in chronic 
infections undergo a stable form of differentiation rather than 
transitioning to a nonfunctional stage. We therefore prefer to 
refer to them as T cells with a chronic phenotype rather than 
calling them exhausted T cells. What determines the extent 
to which T cells acquire this chronic phenotype, how signifi-
cantly T cells with a chronic phenotype differ from acute ef-
fector T cells, and how stable these differences are beyond the 
previously described phenotypic markers remained unclear.
We addressed these fundamental questions by mak-
ing extensive use of newly developed experimental systems, 
which are based on recombinant strains of the chronic LCMV 
clone-13 virus (Flatz et al., 2006). These allowed us to vary 
either the strength of stimulating the TCR or the amount of 
antigen to which T cells become exposed in chronic infec-
tions. Using these systems, we uncovered that antigen amount 
rather than antigen strength is a key determinant of gener-
ating T cells with a chronic phenotype, and we noted that 
key steps toward acquiring this phenotype occur early in per-
sisting infections. We also provide clear evidence that T cell 
accumulation is uncoupled from the phenotype that T cells 
acquire in chronic infections, a notion that strongly supports 
the concept that T cells undergo phenotypic specialization 
when acquiring a chronic phenotype. This differentiation 
concept is further reinforced by showing that T cells can co-
express markers associated with dysfunction of T cells (PD-1) 
and of memory T cells (CD127). In conclusion, we provide 
critical new insights into CD8 T cell biology in chronic infec-
tion and provide highly relevant technological resources and 
approaches for studying T cell responses in chronic infection.
RES ULTS
Low antigen quantity induces an acute T cell 
phenotype in chronic infections
To investigate how antigen quantity impacts T cell responses 
in chronic infections, we devised an experimental setup 
in which P14 TCR-transgenic CD8 T cells (Pircher et al., 
1990) are exposed to different amounts of the LCMV-de-
rived gp33/Db epitope. Our aim was to create a minimally 
manipulated system in which we only alter the amount of 
presented gp33 peptide, whereas all other parameters, such 
as the magnitude of other LCMV-derived peptides, total 
virus load, and level of inflammation, remain constant. We 
achieved this by generating an LCMV clone-13 virus variant 
that expresses a known valine to alanine amino acid substi-
tution, which results in a non–H-2Db–binding peptide KAA 
YNF ATC (Puglielli et al., 2001). By mixing this gp33-de-
prived virus variant (c13 w/o gp33) with wild-type clone-13 
virus, we could alter the amount of gp33 without impacting 
the infectious burden or presentation of any other epitopes 
(Fig. 1 A, left). Importantly, pure wild-type and mixed clone-
13 infections contained similar total virus load at days 7 and 
28 postinfection (p.i.; Fig. 1 B and not depicted). Using next 
generation sequencing techniques, we determined that our 
mixed infection experiments contained ∼14% wild-type 
clone-13 on day 8 and ∼6.5% on day 28, whereas in pure 
wild-type infections, the proportion of nonmutated clone-13 
remained ∼91% (Fig. 1 A, right). These analyses were done 
with at least 15 mice per time point and condition. When 
CFSE-labeled naive P14 T cells were transferred into day 
28 mixed infections, a fraction of the transferred P14 T cells 
began to proliferate, indicating that the gp33 peptide was still 
presented (not depicted). To exclude that this proliferation 
results only from inflammation-driven bystander activation 
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(Chu et al., 2013), we transferred P14 T cells into mice 28 d 
p.i. with only the gp33-deficient clone-13 strain. In these 
hosts, we failed to detect the level of P14 proliferation seen 
in the mixed clone-13 infection (not depicted). Together, this 
demonstrates that some gp33-containing virus persists in the 
mixed group at 28 d p.i.
As a next step, we analyzed the phenotype of T cells in 
the different infections. As expected, P14 T cells primed and 
expanded by high gp33 levels (pure clone-13 group) showed 
the expected exhausted or chronic phenotype; they expressed 
high levels of PD-1 and LAG-3, and only a small fraction 
of cells that produced IFN-γ in response to brief ex vivo 
gp33 restimulation cosecreted TNF (Fig. 1, C–E). In contrast, 
P14 T cells stimulated by low gp33 levels in mixed infection 
lacked expression of inhibitory receptors (PD-1 and LAG-3) 
and displayed a cytokine secretion profile (i.e., high ability 
to cosecrete IFN-γ and TNF) typically found among T cells 
in acute infections such as with LCMV Armstrong (Fig. 1, 
C–E). The same outcome was observed when C57BL/6 
mice without a P14 transfer received a mixed infection. In 
this case, endogenous polyclonal T cells showed an acute phe-
notype and resembled the response of P14 cells (Fig.  1, F 
and G). In contrast, T cells specific for another LCMV gly-
coprotein-derived epitope (gp276–284) remained unaltered 
and showed a chronic phenotype in either mixed or pure 
infections (Fig. 1 H and not depicted). All these observations 
highlight that in the chosen experimental strategy, we indeed 
only influenced the response of gp33-specific T cells with-
out altering the quality or quantity of the T cell response to 
other epitopes. Of note, the strict segregation into an acute or 
Figure 1. Selective generation of effector T cells with an acute or chronic phenotype in chronic LCMV infections. (A, left) Schematic description 
of the infections applied to mice. C57BL/6 mice were infected either with 2 × 106 PFU wild-type (wt) LCMV clone-13 (pure group) or with a combined dose of 
2 × 106 PFU consisting of 0.66 × 106 PFU wild-type LCMV clone-13 and 1.33 × 106 PFU LCMV clone-13 strain A3, which lacks (w/o) the gp33 epitope (mixed 
group). (Right) C57BL/6 mice grafted with CD45.1+ congenic P14 transgenic CD8+ T cells received the described pure or mixed LCMV infection. 8 or 28 d p.i., 
LCMV virus was received from blood samples and analyzed through deep sequencing. Shown are the mean percentages of wild-type gp33 (KAV YNF ATC) 
obtained for all mice (n = 15 per time point and condition). (B–D and F) 4 wk p.i., virus titers in the blood (B) and PD-1 (C) and LAG-3 (D) expression among 
P14 T cells or in a series of experiments without P14 T cells among gp33-tetramer+ CD8+ T cells (F) were determined. Shown are representative histograms 
and mean fluorescence intensity (MFI) of P14 T cells compared with time-matched LCMV Armstrong–infected mice (white; C and D) or gp33-tetramer+ 
CD8+ T cells (F). Arm, Armstrong; LOD, limit of detection. (E, G, and H) At week 4 p.i., splenocytes were in vitro restimulated with gp33 or gp276 and ana-
lyzed for the intracellular expression of IFN-γ and TNF. Shown is the fraction of IFN-γ+ cells that coproduces TNF for P14 T cells (E) and endogenous (endo) 
T cells responding to gp33 (G) or gp276 (H). Each symbol in B, E, G, and H represents an individual mouse; small horizontal lines indicate the mean. Data are 
representative of at least three experiments with at least four mice per group. Error bars represent SEM.
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chronic phenotype critically depends on the ratio of c13 w/o 
gp33 and wild-type LCMV clone-13 virus. Increasing the 
proportion of wild-type virus augmented PD-1 expression 
by P14 T cells, whereas the fraction of IFN-γ– and TNF–co-
producing cells declined (not depicted).
In line with the cytokine and PD-1 expression pro-
files, the majority of pure LCMV clone-13–primed P14 
T cells were Eomes+ and T-betlow, whereas T cells primed by 
mixed infection were almost exclusively T-bethigh and Eomes− 
(Fig. 2 A). This resembles the T-box transcription factor profile 
that has previously been established for T cells in chronic or 
acute LCMV infections (Paley et al., 2012), except that we 
generated cells with an acute phenotype in a chronic infection. 
Interestingly, P14 T cells exposed to low gp33 levels in mixed 
infections expressed KLRG-1, whereas P14 T cells expanded 
in pure clone-13 wild-type infections behaved as expected 
from prior studies (Wherry, 2011; Speiser et al., 2014) and were 
KLRG-1 negative (Fig. 2 B; Wherry et al., 2007). Of additional 
interest is the observation that the vast majority of P14 T cells 
from both types of infection did not up-regulate expression 
of CD127 as in an LCMV Armstrong infection (Fig. 2 C), 
indicating that T cell populations with an effector phenotype 
can be maintained over periods much longer than the time 
span typically seen in acute infections. Most importantly, these 
long-term effector cells still expressed granzyme B, although 
to a lower extent than effector cells obtained from a day 8 
Armstrong infection (Fig. 2 D). To test their effector capacity, 
we injected peptide-loaded target cells into pure and mixed 
week 4 clone-13–infected mice and, as a reference, into day 8 
Armstrong-infected mice. Unexpectedly, after a 4–5-h obser-
vation period, we completely failed to detect residual target 
cells in any of the groups (not depicted). Even after 2 h, all cells 
were eliminated in the Armstrong group, whereas some target 
cells remained in both chronic groups, although more were 
eliminated from the pure infection group (Fig. 2 E). Given the 
extremely short (2 h) observation period, it remains unclear 
how relevant the measured difference is, but it is clear that 
T cells of either phenotype effectively exert effector function, 
and cells with the chronic phenotype might do so slightly 
better. We predominantly attribute the more effective elimi-
nation by the day 8 cells in Armstrong infection to the higher 
abundance of P14 T cells compared with the number of cells in 
the chronic infections and also to a higher activity level of cells 
at the acute compared with the chronic phase of an infection 
(see Fig. 5). This higher activity in day 8 Armstrong mice does 
not contradict our key finding that PD-1 expression levels and 
the cytokine profile do not reflect the cell-intrinsic cytolytic 
potential of T cells in chronic infections when acting against 
PD-L1–negative target cells in persisting infections.
In summary, the data presented in this section demon-
strate an experimental system that selectively generates in 
chronic LCMV clone-13 infections T cells with a phenotype 
similar to cells found in acute infections. Furthermore, the 
level of antigen exposure modulates whether T cells develop 
an acute or chronic phenotype within this system.
Proliferative capacity is uncoupled from the phenotype of  
T cells in chronic infections
As a next step, we analyzed the proliferative capacity of T cells 
in pure and mixed LCMV infections. To our surprise, antigen 
amount impacted neither the number of P14 T cells at day 8 
and 28 p.i. (Fig. 3, A and B) nor the number of endogenous 
gp33-specific T cells (Fig.  3  C). The day 28 outcome was 
very unexpected given that P14 T cells from pure and mixed 
infections strongly differed in PD-1 expression levels and be-
cause P14 T cells in the high antigen dose group showed a 
cytokine profile that is typically viewed to mark exhausted 
T cells (Fig. 1, C and E). By measuring BrdU incorporation, 
we observed that T cells continued to proliferate in both types 
of persisting infection, although at a slightly higher rate in 
pure infections (Fig. 3 D). Given the similar T cell numbers 
in both setups, we considered that this slightly higher prolif-
eration rate is counterbalanced by a minor elevation in the 
cellular death rate. Overall, we therefore concluded that dif-
ferences in the level of PD-1 expression had no major impact 
on the net balance between proliferation and T cell survival.
When P14 T cell populations with an acute or chronic 
phenotype were isolated at day 28 p.i. from mixed or pure 
LCMV clone-13–infected mice and transferred into naive 
hosts, both populations showed in five replicate experiments 
a comparable reexpansion capacity 8 d after challenge that 
ranged from absolutely similar expansion to maximally five-
fold higher expansion of T cells with an acute phenotype 
(Fig.  3  E). These minor differences might reflect a slightly 
lower reexpansion capacity of T cells with a chronic phe-
notype. Another nonmutually exclusive explanation is that 
T cell populations isolated from pure infections might contain 
a lower number of expandable precursor cells than those iso-
lated from mixed infections. Compared with a similar-sized 
transfer of bona fide memory cells (isolated 28 d after an 
LCMV Armstrong infection), the reexpansion magnitude 
of T cells from both types of chronic infections appeared 
small. Nonetheless, their expansion capacity was comparable 
with that of a P14 T cell graft obtained from day 8 Arm-
strong-infected mice (Fig. 3 E).
Altogether, the observed response kinetics clearly indi-
cate that the accumulation of T cells, either after primary or 
secondary challenge, is uncoupled from the phenotype T cells 
acquire in a chronic infection. Moreover, our data reveal that 
T cells with different phenotypes do not differ in their expan-
sion capacity, which strongly suggests that they do not differ 
in their net proliferation or survival kinetics.
Early TCR stimulation critically impacts T cell 
differentiation in chronic infections
Virus load in LCMV clone-13–infected C57BL/6 mice de-
clines over time and becomes typically undetectable 4–12 
wk p.i. in the blood and slightly later in secondary lymphoid 
organs, but it persists long term in the kidneys (Matloubian 
et al., 1994). Consequently, T cells are normally exposed to 
low antigen levels in the late phase of a clone-13 infection. 
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Having observed that antigen levels are critical in determin-
ing the acquisition of a chronic phenotype (Figs. 1, 2, and 3), 
we became interested in exploring what would happen if we 
sustained a high level of antigen exposure in the late stage of 
a clone-13 infection. To address this, we took advantage of 
Vβ5 TCR β chain– only transgenic mice. These mice express 
the same TCR β chain as H-2Kb/ovalbumin-specific OT-1 
TCR-transgenic mice but endogenously rearranged TCR α 
chains (Zehn et al., 2007). This results in a polyclonal TCR 
repertoire that is biased toward recognizing ovalbumin and is 
severely impaired in responding to LCMV-derived antigens 
(not depicted; Utzschneider et al., 2013). When infected with 
LCMV clone-13, these mice show stable high virus titers 
(Fig. 4 A). Of particular importance is the fact that on day 
8 p.i., they show a less than twofold difference in viral titers 
compared with C57BL/6 mice (Fig. 4 B). This difference be-
comes more prominent (10-fold) on day 28 p.i. (Fig. 4 C), as 
viremia persists in Vβ5 mice (Fig. 4 A). Of note, the presence 
of P14 T cells did not alter total virus load in Vβ5 mice (not 
depicted), and CFSE-labeled P14 T cells proliferated mas-
sively when transferred into Vβ5 mice at 28 d p.i. Moreover, 
when we recovered virus from chronically infected Vβ5 mice 
Figure 2. Properties of T cells with an acute or chronic phenotype in chronic LCMV infections. (A–D) C57BL/6 mice grafted with CD45.1+ con-
genic P14 T cells received a pure or mixed LCMV clone-13 infection (see Fig. 1 A for details). In some cases, an LCMV Armstrong (Arm) reference group was 
included. 4 wk p.i., P14 T cells were analyzed for T-bet and Eomes expression levels, whereby the plots show the percentage of Eomes-expressing cells (A); 
KLRG-1 expression (black line [left], pure P14; blue line [right], mixed P14; gray shadow, host CD8+ T cells; B); CD127 and PD-1 expression (C); and granzyme 
B expression (D; colors as in B plus P14 T cells from a day 8 Armstrong infection [dotted line]). (E) 4–6 wk p.i., C57BL/6 mice received gp33 peptide–pulsed 
CFSE+CD45.1+ and control CFSE+CD45.2+ splenocytes to test the cytolytic activity of P14 T cells in mixed and pure infection. Day 8 LCMV Armstrong–infected 
and naive mice served as positive and negative controls. The fraction of eliminated CFSE+CD45.1+ cells was enumerated 2 h after transferring the target cells. 
Data are representative of two (A, B, D, and E) or four (C) experiments with at least four mice per group and with similar results. Statistical analysis was by 
unpaired Student’s t test. **, P < 0.01. Error bars represent SEM.
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at day 28 and used it to infect naive P14-containing C57BL/6 
mice, the P14 T cells expanded, indicating that they contin-
ued to present the gp33 peptide (not depicted). Comparing 
the phenotype of P14 T cells in low or high LCMV clone-
13 titer C57BL/6 or Vβ5 hosts, we noted statistically signif-
icant differences in the level of IFN-γ secretion, the ability 
to coproduce TNF and IFN-γ, and the expression levels of 
PD-1 (Fig. 4, D–F). However, we argue that these are mar-
ginal differences compared with the profiles seen among cells 
with an acute phenotype in mixed LCMV infections. Thus, 
we concluded that despite the elevated antigen and virus ex-
posure levels in chronically infected Vβ5 mice, we did not ob-
serve major phenotypic differences or signs of exhaustion in 
P14 T cells obtained from Vβ5 compared with P14 T cells in 
C57BL/6. Remarkably, even P14 T cell populations harvested 
4 or 20 wk after infecting Vβ5 mice with LCMV clone-13 
underwent robust secondary expansion after transfer into 
acutely infected C57BL/6 mice (Fig. 4 G and not depicted).
We also applied the mixed infection strategy (Fig. 1 A) 
to Vβ5 mice. Similar to what was observed in C57BL/6 hosts, 
T cells retained an acute phenotype in mixed infections and 
a chronic one in pure infections (Fig. 5, A and B). The phe-
notypic outcome in the mixed infected mice surprised us be-
cause we calculated that the amount of wild-type virus that 
is present in day 28 mixed infected Vβ5 hosts is very similar 
to the amount of total LCMV virus in day 28 pure wild-type 
infected C57BL/6 hosts. This assessment takes into account 
that although wild-type virus is only 5–8% of total virus in 
mixed infected Vβ5 mice at day 28 (Fig. 5 C), they contain 
at this time point 10-fold more total virus than C57BL/6 
mice (Fig. 4 C). Therefore, both infections contain in absolute 
terms a similar amount of wild-type clone-13 virus (Fig. 5 D).
Despite the similar level of virus and antigen exposure, 
P14 T cells in mixed infected Vβ5 mice maintain an acute 
phenotype, whereas P14 T cells in pure clone-13–infected 
C57BL/6 mice show a chronic phenotype. In contrast, P14 
T cells in mixed infected Vβ5 or C57BL/6 mice are exposed 
to similar antigen and virus levels during the acute phase of 
the response (Fig. 4 B). We therefore conclude that the pheno-
type correlates with the levels of antigen exposure in the early 
but not in the late phase of chronic infection. Thus, the data 
shown in Figs. 4 and 5 provide strong evidence that the deci-
sion to acquire an acute or chronic phenotype is made at early 
time points in an infection.
Of note, we also assessed the effector capacity of P14 
T cells obtained from 4–5-wk mixed and pure infected Vβ5 
mice, but all target cells were readily eliminated (not de-
picted). Additionally, we assessed effector capacity using in 
Figure 3. Synchronous expansion kinetics 
of T cells with or without a chronic phe-
notype. (A–E) C57BL/6 mice were grafted with 
CD45.1+ congenic P14 T cells and infected with 
a pure or mixed LCMV clone-13 infection as 
indicated in Fig. 1 A. As a control, we also in-
fected C57BL/6 mice grafted with CD45.1+ con-
genic P14 T cells with LCMV Armstrong (Arm). 
(A and B) Absolute numbers of splenic P14 
T cells were measured on day 8 (A) or 28 (B) p.i. 
(C) Similarly, C57BL/6 mice (without P14) were 
infected with a pure and mixed LCMV clone-
13 infection, and gp33-tetramer+ CD8+ T cell 
numbers were determined. (D) Representative 
flow cytometry (left) showing BrdU incorpo-
ration by P14 T cells between days 20 and 26 
p.i. and percentage of BrdU+ among P14 T cells 
(right). (E) At week 4 p.i., P14 T cells were reiso-
lated and transferred into naive secondary 
C57BL/6 hosts, which were then infected with 
LCMV Armstrong. P14 T cells harvested 8 or 
28 d after an acute Armstrong infection were 
transferred as a reference. Shown is the calcu-
lated fold expansion of the P14 T cell popula-
tion 8 d after the LCMV Armstrong challenge. 
The calculation estimates a 10% take of trans-
ferred P14 T cells. Symbols represent individual 
mice; horizontal lines show the mean. Data are 
representative of two (C) or at least four ex-
periments with at least three mice per group. 
Statistical analysis was by unpaired Student’s t 
test. *, P < 0.05. ns, not significant.
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vitro cytotoxicity assays, allowing us to precisely control the 
effector to target ratio. Interestingly, we found that day 28 
T cells with an acute or chronic phenotype were equally ef-
fective but weaker than day 8 effector cells (Fig.  5 E). Al-
though the reason for the lower effector capacity of the day 
28 T cells remains unclear, the data further support our con-
clusion of a lack of correlation between the phenotype and 
intrinsic effector capacity of T cells in chronic infection.
Even persisting low-affinity TCR stimulation 
induces a chronic phenotype
The population of T cells that responds to any foreign an-
tigen is highly diverse and comprises a TCR repertoire in 
which individual receptors differ in their binding affinity to 
the stimulating peptide-MHC (pMHC). Such differences are 
known to critically impact T cell responses in acute infec-
tions (Zehn et al., 2009), but how pMHC recognition influ-
ences T cell differentiation and function in chronic infections 
has been a long-standing question. We followed the strategy 
illustrated in Fig. 6 A and developed a well-controlled ex-
perimental system, which allowed us to address this issue. We 
screened a pool of 95 single amino acid–substituted altered 
peptide ligands (APLs) of the LCMV-derived gp33 peptide. 
We selected 25 APLs binding similarly well to H-2Db but 
which differ in their potency of stimulating P14 T cells. The 
latter was determined by exposing P14 T cell lines to titrated 
peptide doses and measuring the concentration needed to in-
duce half-maximum IFN-γ secretion (not depicted). Taking 
advantage of a previously described reverse genetics approach 
(Flatz et al., 2006, 2010), we developed 25 LCMV clone-13 
strains encoding the selected APL in place of the wild-type 
sequence. Unsurprisingly, most mutant viruses failed to cause 
chronic infection in C57BL/6 mice because the gp33 peptide 
is derived from the glycoprotein that mediates LCMV uptake 
(Kunz et al., 2001). Nonetheless, we identified a variant virus, 
C6 (KAV YNF CTC), that carries a weak P14 T cell agonist 
(Fig. 6 B) and that shows a virus persistence pattern in the 
blood and kidneys that resembles the kinetics of wild-type 
LCMV clone-13 (not depicted). Of note, the C6 variant was 
the weakest ligand we identified that still induces P14 acti-
vation in vivo. An F4 variant was slightly weaker in stimu-
lating P14 T cells in vitro but gave inconsistent results and 
in most cases failed to activate P14 T cells (not depicted). We 
therefore concluded that C6 is at the lowest affinity that still 
Figure 4. High virus titer in the chronic phase of infection causes only minor changes in the T cell phenotype. (A) Vβ5 mice were infected with 
2 × 106 PFU LCMV clone-13 infection. Virus titers in the blood were determined at various time points p.i. LOD, limit of detection. (B–G) Vβ5 or C57BL/6 
mice grafted with CD45.1+ congenic P14 T cells were infected with LCMV clone-13. (B and C) Virus titers in the blood on day 8 (B) or 28 (C) p.i. (D and E) 
Week 4 splenocytes were in vitro restimulated with gp33 and analyzed for intracellular expression of IFN-γ and TNF. Shown are the frequencies of IFN-γ+ 
P14 T cells (D) and the fraction of IFN-γ+ cells that coproduce TNF (E). (F) PD-1 expression and mean fluorescence intensity (MFI) on P14 T cells (black) 
compared with the endogenous CD8+ T cell population in both hosts (gray shadows). Error bars represent SEM. (G) At 4 wk, P14 T cells were reisolated and 
transferred into naive secondary Vβ5 or C57BL/6 hosts, which were then infected with LCMV Armstrong. Shown is the fold expansion of the transferred P14 
population assuming a 10% take of transferred cells. ns, not significant. Each symbol in A–E and G represents an individual mouse; small horizontal lines 
indicate the mean. Data are representative of at least two experiments with at least three mice per group. Statistical analysis was by unpaired Student’s t 
test. *, P < 0.05; **, P < 0.01.
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activates P14 T cells. Importantly, wild-type and C6 clone-13 
induce similar numbers of gp276-specific T cells with iden-
tical PD-1 expression and cytokine secretion profiles (Fig. 6, 
C–E). This indicates that both strains cause a chronic infec-
tion of comparable severity.
To study the T cell response to low-affinity epitopes in 
chronic infection, we transferred P14 T cells into C57BL/6 
host mice and infected them with wild-type or C6 LCMV 
clone-13. High- and low-affinity T cells underwent similar 
expansion until day 8 p.i. Subsequently, the high-affinity cells 
expanded further, and expansion usually peaked between days 
10 and 15 p.i., whereas low-affinity cells started to decline in 
numbers after day 8 p.i. (Fig. 7 A). This revealed that high- and 
low-affinity stimulated P14 T cells in chronic infections follow 
essentially the same kinetic pattern as high- and low-affinity 
T cells in acute infections, where it is known that initial T cell 
expansion is independent of the strength of TCR stimula-
tion but that strength determines the time point when T cell 
numbers decline (Zehn et al., 2009, 2010). Phenotypic anal-
ysis performed at days 8, 28, and 60 p.i. revealed a higher de-
gree of PD-1 expression and lower capacity to cosecrete TNF 
and IFN-γ at all time points among high- compared with 
low-affinity stimulated P14 T cells (Fig. 7, B–G). Together, the 
data indicate that strongly stimulated T cells with a chronic or 
exhausted phenotype expand more vigorously in a persisting 
LCMV infection than phenotypically less exhausted low-af-
finity stimulated T cells (Fig.  7 A). Furthermore, we noted 
that the relative difference in PD-1 expression and cytokine 
secretion capacity observed between high- and low-affinity 
stimulated P14 T cells did not change between days 8 and 60. 
We interpret this finding as additional strong evidence that 
critical steps toward acquiring a chronic phenotype are initi-
ated in the early phase of a chronic infection. This notion of 
an early occurring differentiation is also in line with the data 
shown in Figs. 4 and 5, in which persisting high virus titers in 
the later phase of an LCMV clone-13 infection did not alter 
the phenotype or functional profile of T cells.
Next, we investigated the levels of Eomes and T-bet 
expression by high- and low-affinity stimulated P14 T cells. 
Irrespective of the aforementioned variations in PD-1 expres-
sion and cytokine secretion, we saw no major differences, and 
about half of the P14 T cells in both conditions were Eomes+ 
T-betlow (Fig.  7  H). Taking into account that low-affinity 
T cells express high Eomes levels, express at least a low level 
of PD-1, and show an impaired cytokine secretion profile 
compared with LCMV Armstrong–stimulated cells, we con-
clude that even low-affinity stimulated T cells acquire cardi-
nal features of the chronic infection phenotype. Moreover, it 
Figure 5. Antigen dose during the early infection 
phase determines the T cell phenotype. (A and B) 
Vβ5 mice grafted with CD45.1+ congenic P14 T cells 
were infected with pure or mixed LCMV clone-13 in-
fections (as described in Fig. 1 A). At week 4 p.i., the 
expression of PD-1 (A) and IFN-γ and TNF (B) were 
analyzed by FACS. MFI, mean fluorescence intensity. 
(C) Similar to that described in Fig.  1  A, 28 d after 
mixed infection, blood samples from Vβ5 mice were 
obtained and analyzed. Shown are the percentages 
of wild-type (Wt) gp33 (KAV YNF ATC) or A3 mutant 
(Mut) gp33 (KAA YNF ATC; n = 20 each). (D) Schematic 
illustration showing that wild-type (wt) gp33 (KAV YNF 
ATC) viral load in day 28 pure-infected C57BL/6 mice 
(top, black bar) is similar to the wild-type gp33 portion 
of viral load in day 28 mixed-infected Vβ5 mice (bot-
tom, black bar). (E) P14 T cells from week 4 infected 
Vβ5 mice were quantified and incubated with gp33-
pulsed, 51Cr-labeled EL4 target cells for 5 h. P14 T cells 
obtained from day 8 LCMV Armstrong (Arm d8)–in-
fected Vβ5 mice served as a positive control. Unpulsed 
cells served as a negative control (not depicted). The 
starting effector to target (E:T) ratio was adjusted for 
all infections to similar P14 numbers. 51Cr release was 
analyzed in triplicates and for at least four mice. Each 
symbol in B and C represents an individual mouse or 
the mean of all analyzed mice (E); horizontal lines in-
dicate the mean. Data are representative of at least 
two experiments with at least three mice per group 
or a combination of four experiments (C). Statistical 
analysis was by unpaired Student’s t test. ***, P < 
0.0001. Error bars represent SEM.
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appears that the degree of showing the chronic phenotype is 
uncoupled from the Eomes expression level.
Collectively, our data show that low antigen amounts 
result in an acute T cell phenotype in chronic infections, 
whereas lowering the TCR stimulation strength still triggers 
the formation of T cells with a chronic phenotype. Thus, we 
conclude that epitope/antigen abundance is more critical for 
the induction of a chronic phenotype than the affinity by 
which the TCR becomes activated.
High- and low-affinity stimulation induce CD127+- and 
PD-1+–coexpressing T cells
We noted that a significant fraction of day 28 low-affinity 
stimulated P14 T cells express CD127, a molecule that is typ-
ically expressed by naive or memory T cells in resolved in-
fections (Fig. 8 A). CD127+ P14 T cells can also be detected 
in wild-type clone-13 infections, but high expression levels 
and a clearly separated population form at much later time 
points than after low-affinity stimulation (Fig. 8 B). None-
theless, both observations show that viral persistence does not 
preclude that some cells reexpress the memory T cell marker 
CD127. Interestingly, even on day 80, the fraction of CD127+ 
cells was twice as large in low- compared with high-affinity 
stimulated T cells, indicating that low-affinity stimulation en-
hances the formation of T cells with a memory phenotype 
in chronic infections.
To our surprise, we noted on day 80 p.i. that the CD127+ 
high- or low-affinity stimulated P14 T cells still expressed sig-
nificant levels of PD-1 compared with LCMV Armstrong–
derived bona fide memory T cells on day 80 p.i. (Fig. 8 C). 
This was also true for low-affinity stimulated CD127+ P14 
T cells at day 28 (not depicted). Although this coexpression 
appears very unexpected at first glance, PD-1 expression by 
CD127+ T cells is consistent with the fact that when T cells 
from chronic infections are transferred into naive mice and 
reexpanded in an acute infection, they maintain high expres-
sion of PD-1 (Utzschneider et al., 2013). Despite the dif-
ference in numbers of CD127+ P14 T cells after high- and 
low-affinity stimulation, their PD-1 expression levels were 
similar at day 80 (Fig.  8  C). We then tested the ability of 
the high- and low-affinity stimulated CD127+ T cell popu-
lations to undergo secondary expansion. For this, we sorted 
low- and high-affinity stimulated CD127+ P14 T cells 70 d 
p.i., transferred them into naive mice, and infected them 
with LCMV Armstrong. At day 8, we noted a similar reex-
pansion magnitude for both CD127+ P14 T cell populations 
Figure 6. Generation of LCMV clone-13 strains expressing 
low-affinity APLs. (A) Schematic illustration of selecting LCMV 
clone-13–compatible, gp33-derived APLs for P14 TCR-transgenic 
T cells. 95 APLs were in vitro and in vivo screened for their potency to 
stimulate P14 T cell lines, their ability to bind to H-2Db (determined 
by MHC surface stabilization on TAP [transporter associated with an-
tigen processing]-deficient RMA-S cells), and absence of interference 
with LCMV clone-13 infection kinetics. APLs showing a functional 
avidity distinct from the normal gp33 peptide but similar MHC bind-
ing were selected to generate recombinant LCMV clone-13 strains. 
With the exception of KAV YNC ATC (C6), all other APLs were excluded 
because they did not meet at least one selection criteria. (B) IFN-γ 
dose–response curves of transgenic P14 T cells responding to normal 
gp33 or C6 peptide. (C–E) C57BL/6 mice were infected with 2–4 × 106 
PFU LCMV clone-13 wild type (Wt) or C6. (C) 4 wk p.i., splenocytes 
were analyzed for absolute numbers of gp276 tetramer+ CD8+ T cells. 
(D) Mean fluorescence intensity (MFI) of PD-1 expression on gp276+ 
T cells 4 wk p.i. with wild-type and C6 clone-13 or LCMV Armstrong 
(Arm). Error bars represent SEM. (E) Splenocytes from the same ex-
periment were in vitro restimulated with gp276 and analyzed for in-
tracellular expression of IFN-γ and TNF. Shown are the frequencies 
of TNF+ cells among total endogenous IFN-γ+ T cells. Each symbol 
in B represents the mean of three individual titrations and in C and 
E, an individual mouse; horizontal lines indicate the mean. Data are 
representative of at least three independent experiments, each with 
at least four mice per group. Statistical analysis was by unpaired Stu-
dent’s t test. *, P < 0.05.
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Figure 7. Chronic low-affinity stimulation leads to 
an intermediate chronic phenotype. (A–H) C57BL/6 
mice grafted with CD45.1+ congenic P14-transgenic CD8+ 
T cells were infected with wild-type (Wt) LCMV clone-13, 
the clone-13 strain containing the low-affinity gp33-C6 
epitope (C6; described in Fig. 6), or LCMV Armstrong (Arm). 
(A) Frequency of P14 T cells among total CD8+ T cells in 
the blood. The gray columns indicate days 8, 28, and 60, 
which correspond to the analyses presented in B–G. (B, D, 
and F) Splenocytes were in vitro restimulated with gp33 
and analyzed for intracellular expression of IFN-γ and TNF. 
(C, E, and G) PD-1 mean fluorescence intensity (MFI) on 
P14 T cells. (H) Eomes and T-bet expression in P14 T cells 
and frequency of Eomes+ P14 T cells 28 d p.i. Each sym-
bol in A represents the mean of five mice and in B, D, F, 
and H, an individual mouse; small horizontal lines indicate 
the mean. Data are representative of two (A–C and F–H) 
or three (D and E) independent experiments with at least 
four mice per group. Statistical analysis was by unpaired 
Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.0001. 
Error bars represent SEM. ns, not significant.
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(Fig. 8 D). Thus, on a per cell basis, low- and high-affinity 
primed CD127+ T cells have similar reexpansion capacity.
Together, our observations indicate that the strength of 
the stimulus T cells receive early in a chronic infection im-
pacts expansion magnitude and phenotype. In contrast, the 
differences level out in the emerging memory compartment 
as virus titers decline over time. Thus, low- and high-affinity 
stimulation in chronic infection generate T cells with com-
parable memory qualities.
DIS CUS SION
T cells derived from persisting infections perform in many 
functional tests less well than T cells obtained from resolved 
infections. This leads to the conclusion that they are severely 
functionally impaired. However, such comparisons have sev-
eral limitations and confounding factors, including finding a 
suitable time point for side-by-side evaluation. For instance, 
when week 4 Armstrong T cells are compared with T cells 
from a week 4 clone-13 infection, one is essentially compar-
ing resting T cells with activated T cells from a persisting in-
fection. Moreover, acute and chronic LCMV strains differ in 
the magnitude of inflammation they cause, the level of tissue 
destruction, antigen presentation kinetics, and tissue tropism 
of the virus (Sevilla et al., 2000; Smelt et al., 2001; Beura et 
al., 2015). All of these aspects make the comparison rather dif-
ficult to interpret. Thus, it has remained unclear to what de-
gree functional differences between T cells from resolved or 
chronic infections relate to the particular effector phenotype 
they display (exhausted vs. acute phenotype) and how much 
of the response pattern can be attributed to the fact that the 
comparisons use cells at different stages of activation and from 
different environments.
While studying how differences in the magnitude of 
antigen exposure impact T cell differentiation in chronic 
infections, we noted that T cells can still acquire an acute 
effector phenotype if exposed to low quantities of antigen. 
Interestingly, these acute T cells persist without showing signs 
of transitioning into memory T cells and remain CD127− 
and KLRG-1+. This created a unique experimental situation 
and allowed us to compare acute and chronic phenotype T 
cells in exactly the same environment. Given that total virus 
titers, severity of infection, overall T cell response, and pre-
sentation of all LCMV epitopes except gp33 are identical in 
our setup, we argue that we are using a minimally manipu-
Figure 8. CD127-expressing T cells in chronic infections coexpress PD-1. (A–D) C57BL/6 mice grafted with CD45.1+ congenic P14-transgenic CD8+ 
T cells were infected with LCMV Armstrong (Arm), LCMV clone-13 (wild type [Wt]), or LCMV clone-13 C6 (C6). (A and B) CD127 expression on splenic P14 
T cells (black, wild type; orange, C6; gray, Armstrong) on day 28 (A) or day 80 (B). Shown are representative flow plots at days 28 and 80 and data for all mice 
in one experiment at day 80. (C) Representative flow cytometry histogram of PD-1 expression on the CD127+ P14 T cells shown in B and mean fluorescence 
intensity (MFI) of all mice. Error bars represent SEM. (D) 70–80 d p.i., CD127+ P14 T cells were sorted from the primary host and transferred into naive 
secondary C57BL/6 recipients, which were then infected with LCMV Armstrong. Depicted is the fold expansion of the CD127+ P14 population derived from 
wild-type or C6 LCMV clone-13–infected mice. Reexpansion was calculated estimating a 10% take of transferred P14 T cells. Symbols in B and D represent 
individual mice; horizontal lines indicate the mean. Data are representative of four (day 28) or two (day 70–80) independent experiments, with at least four 
mice per group. Statistical analysis was by unpaired Student’s t test. **, P < 0.01. ns, not significant.
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lated experimental system. To our surprise, we uncovered that 
T cells with or without a chronic phenotype underwent sim-
ilar primary expansion, were maintained in equal numbers, 
and even showed a similar secondary expansion potential. We 
therefore conclude that T cells in chronic infections undergo 
a form of differentiation that, at least initially, does not impact 
their net accumulation.
Our observations do not rule out that T cells with a 
chronic phenotype differ fundamentally from acute effector 
T cells when it comes to performing effector functions, for 
instance, against PD-L1 or other inhibitory ligands expressing 
target cells. In fact, we consider that the exhausted phenotype 
might have evolved because such T cells can be conditionally 
switched off by engaging the PD-1/PD-L1 axis or other in-
hibitory receptors. Moreover, the lower cytokine production 
capacity of cells with a chronic phenotype might render them 
less aggressive and less proinflammatory. Such effector T cells 
would be advantageous in preventing immunopathology be-
cause the strong and aggressive immune responses found in an 
acute infection could be detrimental in persistently infected 
hosts (Cornberg et al., 2013; Doedens et al., 2013). Thus, the 
exhausted phenotype might constitute an optimized effector 
phenotype that creates an equilibrium between virus control 
and tissue damage (Virgin et al., 2009) while having the option 
to block unwanted effector T cell function against vulnerable 
tissues or structures (Speiser et al., 2014). This principle has 
been well illustrated by studies showing that endothelial cell 
wall integrity during chronic infections critically depends on 
the presence of PD-L1+ endothelial cells (Frebel et al., 2012). 
Similarly, failure to acquire a chronic phenotype was shown 
to correlate with more severe pathology. For example, the 
transcription factor HIF1a is critical for generating T cells 
with an exhausted phenotype, and its absence correlates with 
strong immunopathology caused by retention of T cells with 
an acute phenotype (Doedens et al., 2013). This strongly sup-
ports the concept that attenuating T cell function through 
acquiring a chronic phenotype is essential for host integrity.
Of note, although day 28 cells of either phenotype 
showed similar effector capacity in in vitro tests, they were less 
effective than day 8 T cells obtained from LCMV Armstrong–
infected mice. It is important to consider that day 8 and 28 
T cells differ in their activation status. Moreover, they origi-
nate from host environments with distinct cytokine profiles, 
levels of inflammation, and metabolic profiles. Therefore, the 
implications of the day 8 versus day 28 comparisons remain 
unclear, and it needs to be determined whether the two day 
28 populations are equally hypofunctional or equally func-
tional against PD-L1–negative targets.
Another key observation of our study is the generation 
of CD127+-expressing pathogen-specific T cells in chronic 
LCMV infections. This observation, along with the finding 
that we can reexpand a fraction of T cells from chronic in-
fection, indicates that long-term exposure to antigen and in-
flammation does not preclude T cells from segregating into 
antigen-dependent effector T cells and antigen-independent 
memory T cells. Nonetheless, there appears to be a strong link 
between total virus load and CD127 expression, as a discrete 
CD127+ population can only be seen in C57BL/6 mice at >4 
wk of infection, when virus load has significantly dropped. 
In line with this, only very low levels of CD127+-express-
ing cells can be found in Vβ5 mice in which LCMV clone-
13 persists at very high titers. Interestingly, the frequency of 
CD127+ cells correlates with the strength of TCR stimula-
tion, as CD127 expression could be consistently detected at 
earlier time points and at higher frequencies among low-af-
finity stimulated T cells. In contrast, the amount of antigen 
(mixed vs. pure experiments) did not influence the kinetics 
of CD127 reexpression. Much to our surprise, we uncovered 
that CD127+ cells in chronic infections can coexpress PD-1, 
whereas memory T cells from acutely resolved infections re-
mained PD-1−. As unexpected as this coexpression appears at 
first glance, it is well in line with our hypothesis that T cells 
undergo a stable form of differentiation and that the exhausted 
phenotype can be propagated through memory-equivalent 
T cells (Utzschneider et al., 2013; Speiser et al., 2014).
A long-standing question in the field has been what de-
termines whether T cells acquire an exhausted phenotype. So 
far, high virus titers (Day et al., 2006), limited CD4 T cell help 
(Zajac et al., 1998; Blackburn et al., 2009), large numbers of 
antigen-positive target cells (Mueller and Ahmed, 2009), or 
the absence of IL-21 signaling (Elsaesser et al., 2009; Fröh-
lich et al., 2009; Yi et al., 2009) has been shown to promote 
the generation of this phenotype. Following indications in 
the literature, we considered that the strength of pMHC–
TCR interaction could be another key determining factor 
(Lichterfeld et al., 2007; Viganò et al., 2012). To address this 
in a well-defined experimental setup, we generated APL-ex-
pressing LCMV clone-13 strains. Indeed, we observed that 
low-affinity stimulation correlated with lower PD-1 expres-
sion and a better IFN-γ and TNF cosecretion profile, but 
we did not detect any differences in Eomes expression. This 
strongly contrasted with the phenotype seen after exposing 
T cells to low amounts of high-affinity antigen, which re-
sulted in T cells that show an Eomes, cytokine, and PD-1 
expression profile that resembles T cells found in acutely 
resolved infections. Lower antigen levels mean that a TCR 
engages less frequently with cognate pMHCs. We therefore 
conclude that frequency of TCR stimulation more critically 
impacts T cell differentiation in chronic infections than the 
actual strength of the TCR signal. How this exactly happens 
remains unclear, as lower antigen levels could mean reduced 
serial TCR triggering when a T cell interacts with one DC. 
Alternatively, the interval between engaging antigen-positive 
or -negative DCs or target cells could be reduced. In any case, 
linking T cell differentiation to antigen presentation levels 
means that T cells indirectly sense the pathogen load.
We also provide several lines of evidence that critical 
steps toward acquiring a chronic phenotype occur early and 
not selectively at late stages of chronic infections. Among 
them is the observation that the persisting high virus titers in 
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Vβ5 host mice do not induce a more severe phenotype than 
in C57BL/6 mice. In this respect, it is important to consider 
that virus titers in C57BL/6 and Vβ5 mice are comparable 
during the first 7–10 d p.i., suggesting this interval is crucial 
for determining the phenotype T cells acquire. This model is 
also supported by the observation that low- and high-affinity 
stimulated T cells clearly already differ in PD-1 and cytokine 
expression levels on day 8 p.i., and the differences are subse-
quently stably maintained. Of note, P14 T cells responding to 
a low dose of antigen sustain over time their early acquired 
acute phenotype, precluding that chronic T cell stimulation 
induces an overall gradual loss of function. Our notion of 
an early differentiation contrasts at first glance with adoptive 
transfer experiments, which indicated that depriving T cells 
of antigen too early causes the population to revert back to 
an acute phenotype (Angelosanto et al., 2012). Nonetheless, 
those findings do not necessarily disagree with our conclu-
sions. Rather, we propose that critical steps toward acquiring 
the chronic phenotype occur early and maybe between days 
5 and 8 p.i. Nonetheless, there is a period of plasticity during 
which continuing antigen contacts are required to stably fix 
the phenotype and antigen deprivation might cause cells to 
revert back to an acute phenotype. Moreover, our notion that 
early antigen levels decide which phenotype T cells acquire 
has far-reaching consequences for vaccine design, as it sug-
gests that too high antigen levels bear the risk of inducing the 
unwanted chronic phenotype in a vaccine setting.
Based on all these findings, we conclude that acquiring 
a chronic phenotype reflects an event of cellular differenti-
ation and specialization and not primarily a transition into 
a terminal and nonfunctional stage. Thus, we establish that 
T cells can obtain either a polyfunctional PD-1− phenotype 
or a PD-1+, low cytokine–producing effector phenotype, and 
we demonstrate that the level of antigen exposure is the crit-
ical factor deciding which of the two phenotypes T cells ob-
tain in chronic infections.
MAT ERI ALS AND MET HODS
Mice
C57BL/6 mice were obtained from Charles River. P14 
TCR-α/β transgenic mice (Pircher et al., 1990) were pro-
vided by A. Oxenius (Eidgenössische Technische Hochschule, 
Zurich, Switzerland), and Vβ5 TCR-β–only transgenic mice 
(Zehn et al., 2007) were provided by P. Fink (University of 
Washington, Seattle, WA). Mice were bred and maintained 
in specific pathogen-free facilities and infected in conven-
tional animal facilities of the University of Lausanne. Ex-
periments were performed in at least 6-wk-old mice in 
compliance with the University of Lausanne institutional 
regulations and were approved by the veterinarian authorities 
of the Swiss Canton Vaud.
Infections and virus titer determination
Recombinant APL-expressing LCMV clone-13 strains were 
recovered from cDNA using a previously described reverse 
genetics approach (Flatz et al., 2006, 2010). Double nucleo-
tide changes were introduced to mutate the H-2Db–restricted 
gp33 epitope KAV YNF ATC (wild type) into KAV YNC ATC 
(C6) or KAA YNF ATC (A3), thus reducing the likelihood of 
viral mutational reversion in vivo. All strains were propagated 
in baby hamster kidney (BHK) cells and titrated on Vero cells 
following an established protocol (Battegay et al., 1991). Fro-
zen stocks were diluted in PBS, and 2 × 105 PFU LCMV 
Armstrong was injected intraperitoneally, and 2 × 106 PFU 
wild-type LCMV clone-13 and 4 × 106 PFU LCMV clone-
13-C6 were injected intravenously. Mixed LCMV infections 
were constituted of one third wild-type LCMV clone-13 
(0.66 × 106 PFU) plus two thirds LCMV clone-13-A3 (1.33 
× 106 PFU), which lacks a functional gp33 epitope (Pug-
lielli et al., 2001). Blood samples from LCMV-infected mice 
were shock frozen. Diluted samples were used to infect Vero 
cells, and virus titers were determined using an LCMV focus–
forming assay (Battegay et al., 1991).
Purification of mouse T cells and adoptive T cell transfer
Single-cell splenocyte suspensions were obtained by mashing 
total spleens through a 100-µm nylon cell strainer (BD), and 
red blood cells were lysed with a hypotonic ACK buffer. Trans-
genic CD8+ T cells were isolated using the mouse CD8 T cell 
enrichment kit (Miltenyi Biotech). 2–5 × 103 CD45.1+ naive 
congenic P14 T cells were transferred into naive CD45.2+ 
C57BL/6 mice. P14 T cells were reisolated from infected 
mice by staining total splenocytes with anti-CD8 (clone 53-
6.7; eBioscience), CD45.1 (purified hybridoma supernatant; 
self-conjugated; clone A20), and CD127 (clone eBioSB/199; 
eBioscience). CD8+CD45.1+ or CD8+CD45.1+CD127+ cells 
were isolated by flow cytometry–assisted cell sorting. The 
purity of sorted cells was >99%. In all cases, we confirmed 
that T cells isolated from pure clone-13–infected mice ex-
hibit the chronic phenotype.
Ex vivo T cell activation, expansion, and 
functional avidity tests
Similar to that previously described (Enouz et al., 2012), 
106 P14 T cells were seeded into 24-well plates, stimulated 
with anti-CD3/CD28 Dynabeads (Invitrogen), and cul-
tured in RPMI supplemented with 10% FCS, penicillin/
streptomycin, 5  µM 2-ME, and 5  mM Hepes (all Invitro-
gen). Culture volumes were increased, and additional media 
were added as needed. 50 U/ml human IL-2 (Chiron) was 
added on day 0 and every other day. Cells were analyzed 6–7 
d after the stimulation.
3 × 105 activated P14 T cells were seeded with 105 
RMA cells (which functioned as APCs) into 96-well plates. 
The cells were stimulated with titrated doses of wild-type 
gp33 (KAV YNF ATC) or gp33-C6 (KAV YNC ATC) peptide 
(EMC Microcollections) in vitro for 30 min at 37°C before 
7  µM brefeldin A (Sigma-Aldrich) was added for another 
4.5-h incubation at 37°C. Afterward, cells were washed and 
surface and intracellularly stained.
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Surface and intracellular antibody staining and flow 
cytometry cell sorting of mouse cells
Surface staining was performed for 30 min and with tetramer 
for 90 min at 4°C in PBS supplemented with 2% FCS and 
0.01% azide (FACS buffer) using the following antibodies: an-
ti-CD8α (53-6.7), CD127 (eBioSB/199), LAG-3 (C9B7W), 
and KLRG-1 (2F1; all eBioscience); anti–PD-1 (RMP1-30; 
BioLegend); gp276–286 tetramer (TCMetrix); and anti-CD4 
(GK1.5), CD45.1 (A20), and CD45.2 (clone 104), obtained 
from or custom purified by Bio X Cell and coupled to Pacific 
blue, Alexa Fluor 647, or FITC using labeling reagents from 
Invitrogen. Cells were washed twice and fixed in PBS supple-
mented with 1% formaldehyde, 2% glucose, and 0.03% azide 
for 20 min. Then, cells were washed again and resuspended 
in FACS buffer. For intracellular cytokine staining, cells were 
fixed and permeabilized using the Cytofix/Cytoperm kit (BD) 
and stained with anti–IFN-γ (XMG1.2), TNF (MP6-XT22; 
both from eBioscience), or granzyme B (GB12; Invitrogen). 
T-bet and Eomes staining was performed with a transcrip-
tion factor staining kit (eBioscience) and stained with Eomes 
(Dan11mag) and T-bet (eBio4B10; both from eBioscience).
For flow cytometry sorting, living cells were stained in 10% 
FCS RPMI media and sorted on a FAC SAria instrument (BD).
BrdU administration and staining
LCMV-infected mice were fed with 0.8 mg/ml BrdU (Sig-
ma-Aldrich) in drinking water between days 20 and 26 and 
received a 2-mg BrdU bolus i.p. injection on days 20 and 24 
p.i. On day 26 p.i., splenocytes were intracellularly stained for 
incorporated BrdU with the BD BrdU staining kit.
In vivo cytotoxicity assay
LCMV-infected (weeks 4–6) or naive mice received CFSE+ 
CD45.1+ splenocytes pulsed with gp33 peptide and a non-
pulsed CFSE+CD45.2+ reference population. 5  µM CFSE 
was used to label the cell populations. Cells were pulsed for 
60 min with 5  µM gp33 peptide. 2  h after the transfer of 
the target cells, total splenocytes were harvested and stained 
with anti-CD45.1 (A20; eBioscience) and self-conjugated 
anti-CD45.2 (custom purified from hybridoma 104; Bio X 
Cell) and analyzed by flow cytometry. Using the no-peptide 
reference population, the fraction of eliminated peptide-con-
taining target cells was calculated.
Ex vivo cytotoxicity assay
P14 T cells obtained from LCMV-infected Vβ5 mice were 
quantified and adjusted to equal numbers. As target cells, EL4 
cells were labeled with 200 µCi Cr-51 (PerkinElmer) for 
60–90 min at 37°C. Cells were washed twice and incubated 
with the adjusted number of P14 T cells in the presence or 
absence of gp33 peptide (EMC Microcollections) for 5 h at 
37°C. Maximum release (MR) was measured with target cells 
plus 500 mM HCl, and spontaneous release (SR) was mea-
sured with target cells only. After incubation, supernatant was 
taken from each well, and chromium content was measured 
using a LumaPlate (PerkinElmer). Specific lysis was calculated 
according to the following formula: percent specific lysis = 
(cpmSample − cpmSR)/(cpmMR − cpmSR) × 100.
Next generation sequencing
Blood samples were taken at day 8 or 28 from LCMV-infected 
mice and used to propagate LCMV virus by infecting BHK 
cells. RNA extracted from the infected BHK cells was iso-
lated using the RNeasy Micro kit (QIA GEN) and transcribed 
into cDNA with a Sensiscript Reverse Transcription kit (QIA 
GEN) using an LCMV-specific primer (5′-CAC AGG ACC 
TGC CAG CC-3′). The relevant section of the LCMV gly-
coprotein, which contains the gp33 epitope, was PCR am-
plified with the following primers: 5′-GGT GAT CAA CAT 
TGT CAT TAT TGT GC-3′ and 5′-xxxxxxxxCAC AGG ACC 
TGC CAG CC-3′. All primers contained a unique nucleotide 
barcode (eight nucleotides long, indicated by xxxxxxxx in 
the primer) allowing us to pool different samples for next 
generation sequencing analysis using an Illumina sequencing 
platform (paired-end analysis; 25 million reads).
Data analyses
Flow cytometry measurements of cells were performed on 
an LSR-II flow cytometer (BD). All data were analyzed using 
FlowJo (Tree Star). Graphs were prepared and EC50 concen-
trations were determined with Prism (GraphPad Software). 
The error bars show SEM.
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